{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:34:47Z","timestamp":1793295287342,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recombinant human growth hormone (rhGH) therapy has shown to improve height and body composition in children with Prader\u2013Willi syndrome (PWS), the evidence of early rhGH treatment on motor and mental development is still accumulating. This study explored the time effect on psychomotor development, anthropometric indexes, and safety for infants and young children with PWS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A phase 3, single-arm, multicenter, self-controlled study was conducted in six sites. Patients received rhGH at 0.5\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day for first four weeks, and 1\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day thereafter for up to 52\u00a0weeks. Motor development was measured using Peabody Developmental Motor Scales-second edition, mental development using Griffiths Development Scales-Chinese (GDS-C). Height standard deviation score (SDS), body weight SDS, and body mass index (BMI) SDS were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-five patients were enrolled totally. Significant improvements were observed in height, body weight, and BMI SDS at week 52; GDS-C score showed significant improvement in general quotient (GQ) and sub-quotients. In a linear regression analysis, total motor quotient (TMQ), gross motor quotient (GMQ), and fine motor quotient were negatively correlated with age; however, treatment may attenuate deterioration of TMQ and GMQ. Changes in GQ and locomotor sub-quotient in\u2009&lt;\u20099-month group were significantly higher than\u2009\u2265\u20099-month group. Mild to moderate severity adverse drug reactions were reported in six patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fifty-two-week treatment with rhGH improved growth, BMI, mental development, and lessened the deterioration of motor function in infants and young children with PWS. Improved mental development was more pronounced when instituted in patients\u2009&lt;\u20099\u00a0months old.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12519-022-00653-y","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T22:03:07Z","timestamp":1671832987000},"page":"438-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader\u2013Willi syndrome"],"prefix":"10.1007","volume":"19","author":[{"given":"Ruo-Qian","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qin","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Qing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Fen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Xiu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-5926","authenticated-orcid":false,"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,24]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","volume":"14","author":"SB Cassidy","year":"2012","unstructured":"Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader\u2013Willi syndrome. Genet Med. 2012;14:10\u201326.","journal-title":"Genet Med"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"E1072","DOI":"10.1210\/jc.2012-3888","volume":"98","author":"CL Deal","year":"2013","unstructured":"Deal CL, Tony M, H\u00f6ybye C, Allen DB, Tauber M, Christiansen JS, et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader\u2013Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072\u201387.","journal-title":"J Clin Endocrinol Metab"},{"key":"653_CR3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1210\/jc.2012-1182","volume":"97","author":"EP Siemensma","year":"2012","unstructured":"Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader\u2013Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012;97:2307\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1365-2265.2003.01769.x","volume":"58","author":"C Hoybye","year":"2003","unstructured":"Hoybye C, Hilding A, Jacobsson H, Thoren M. Growth hormone treatment improves body composition in adults with Prader\u2013Willi syndrome. Clin Endocrinol (Oxf). 2003;58:653\u201361.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1515\/JPEM.2004.17.4.591","volume":"17","author":"B Whitman","year":"2004","unstructured":"Whitman B, Carrel A, Bekx T, Weber C, Allen D, Myers S. Growth hormone improves body composition and motor development in infants with Prader\u2013Willi syndrome after six months. J Pediatr Endocrinol Metab. 2004;17:591\u2013600.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ajmg.a.31468","volume":"143A","author":"SE Myers","year":"2007","unstructured":"Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of growth hormone therapy in young children with Prader\u2013Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A. 2007;143A:443\u20138.","journal-title":"Am J Med Genet A"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13023-019-1195-1","volume":"14","author":"A Yang","year":"2019","unstructured":"Yang A, Choi JH, Sohn YB, Eom Y, Lee J, Yoo HW, et al. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader\u2013Willi syndrome: a randomized, active-controlled trial. Orphanet J Rare Dis. 2019;14:216.","journal-title":"Orphanet J Rare Dis"},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000437141","volume":"84","author":"NE Bakker","year":"2015","unstructured":"Bakker NE, Siemensma EP, van Rijn M, Festen DA, Hokken-Koelega AC. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader\u2013Willi syndrome: a randomized controlled trial and longitudinal study. Horm Res Paediatr. 2015;84:231\u20139.","journal-title":"Horm Res Paediatr"},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"e000630","DOI":"10.1136\/bmjpo-2019-000630","volume":"4","author":"CGB Passone","year":"2020","unstructured":"Passone CGB, Franco RR, Ito SS, Trindade E, Polak M, Damiani D, et al. Growth hormone treatment in Prader\u2013Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr Open. 2020;4:e000630.","journal-title":"BMJ Paediatr Open"},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jpeds.2004.08.002","volume":"145","author":"AL Carrel","year":"2004","unstructured":"Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader\u2013Willi syndrome. J Pediatr. 2004;145:744\u20139.","journal-title":"J Pediatr"},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1210\/jc.2009-1389","volume":"95","author":"AL Carrel","year":"2010","unstructured":"Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader\u2013Willi syndrome. J Clin Endocrinol Metab. 2010;95:1131\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"653_CR12","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1016\/j.ridd.2013.05.043","volume":"34","author":"L Reus","year":"2013","unstructured":"Reus L, Pelzer BJ, Otten BJ, Siemensma EP, van Alfen-van der Velden JA, Festen DA, et al. Growth hormone combined with child-specific motor training improves motor development in infants with Prader\u2013Willi syndrome: a randomized controlled trial. Res Dev Disabil. 2013;34:3092\u2013103.","journal-title":"Res Dev Disabil"},{"key":"653_CR13","doi-asserted-by":"publisher","first-page":"e1619","DOI":"10.1542\/peds.2013-3607","volume":"134","author":"L Reus","year":"2014","unstructured":"Reus L, Pillen S, Pelzer BJ, van Alfen-van der Velden JA, Hokken-Koelega AC, Zwarts M, et al. Growth hormone therapy, muscle thickness, and motor development in Prader\u2013Willi syndrome: an RCT. Pediatrics. 2014;134:e1619\u201327.","journal-title":"Pediatrics"},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1365-2265.2007.03126.x","volume":"68","author":"DA Festen","year":"2008","unstructured":"Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit JM, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader\u2013Willi syndrome. Clin Endocrinol (Oxf). 2008;68:919\u201325.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"653_CR15","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1210\/jc.2018-00687","volume":"103","author":"SH Donze","year":"2018","unstructured":"Donze SH, Damen L, Mahabier EF, Hokken-Koelega ACS. Improved mental and motor development during 3 years of GH treatment in very young children with Prader\u2013Willi syndrome. J Clin Endocrinol Metab. 2018;103:3714\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ajmg.a.32137","volume":"146A","author":"U Eiholzer","year":"2008","unstructured":"Eiholzer U, Meinhardt U, Rousson V, Petrovic N, Schlumpf M, l\u2019Allemand D. Developmental profiles in young children with Prader\u2013Labhart\u2013Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet A. 2008;146A:873\u201380.","journal-title":"Am J Med Genet A"},{"key":"653_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0387-7604(03)00102-5","volume":"26","author":"MV Johnston","year":"2004","unstructured":"Johnston MV. Clinical disorders of brain plasticity. Brain Dev. 2004;26:73\u201380.","journal-title":"Brain Dev"},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ddrr.64","volume":"15","author":"MV Johnston","year":"2009","unstructured":"Johnston MV. Plasticity in the developing brain: implications for rehabilitation. Dev Disabil Res Rev. 2009;15:94\u2013101.","journal-title":"Dev Disabil Res Rev"},{"key":"653_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.vh.2020.04.001","volume":"114","author":"CG Martinez-Moreno","year":"2020","unstructured":"Martinez-Moreno CG, Aramburo C. Growth hormone (GH) and synaptogenesis. Vitam Horm. 2020;114:91\u2013123.","journal-title":"Vitam Horm"},{"key":"653_CR20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/9780470373699.speced1552","volume-title":"Encyclopedia of special education","author":"T Maddox","year":"2008","unstructured":"Maddox T. Peabody developmental motor scales. In: Reynolds CR, editors. Encyclopedia of special education. 3rd ed. Hoboken: Wiley; 2008. p. 1521."},{"key":"653_CR21","volume-title":"Growth standard and growth curve of Chinese children","author":"Department of Maternal and Child Health and Community Health, Ministry of Health, People's Republic of China","year":"2009","unstructured":"Department of Maternal and Child Health and Community Health, Ministry of Health, People\u2019s Republic of China. Growth standard and growth curve of Chinese children. Shanghai: Second Military Medical University Press; 2009."},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/978-1-4419-1698-3_1185","volume-title":"Encyclopedia of autism spectrum disorders","author":"R Watling","year":"2013","unstructured":"Watling R. Peabody Developmental Motor Scales (PDMS). In: Volkmar FR, editor. Encyclopedia of autism spectrum disorders. New York: Springer; 2013. p. 2138\u201340."},{"key":"653_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cch.12548","volume":"44","author":"WWY Tso","year":"2018","unstructured":"Tso WWY, Wong VCN, Xia X, Faragher B, Li M, Xu X, et al. The Griffiths Development Scales-Chinese (GDS-C): a cross-cultural comparison of developmental trajectories between Chinese and British children. Child Care Health Dev. 2018;44:378\u201383.","journal-title":"Child Care Health Dev"},{"key":"653_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1507\/endocrj.EJ12-0110","volume":"59","author":"T Isojima","year":"2012","unstructured":"Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, et al. Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J. 2012;59:771\u201380.","journal-title":"Endocr J"},{"key":"653_CR25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1210\/jc.2013-3060","volume":"99","author":"N Friedrich","year":"2014","unstructured":"Friedrich N, Wolthers OD, Arafat AM, Emeny RT, Spranger J, Roswall J, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99:1675\u201386.","journal-title":"J Clin Endocrinol Metab"},{"key":"653_CR26","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","volume":"155A","author":"JL Miller","year":"2011","unstructured":"Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, et al. Nutritional phases in Prader\u2013Willi syndrome. Am J Med Genet A. 2011;155A:1040\u20139.","journal-title":"Am J Med Genet A"},{"key":"653_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/EJE-19-0479","volume":"182","author":"SH Donze","year":"2020","unstructured":"Donze SH, Damen L, Mahabier EF, Hokken-Koelega ACS. Cognitive functioning in children with Prader\u2013Willi syndrome during 8 years of growth hormone treatment. Eur J Endocrinol. 2020;182:405\u201311.","journal-title":"Eur J Endocrinol"},{"key":"653_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/01.pep.0000226746.57895.57","volume":"18","author":"BH Connolly","year":"2006","unstructured":"Connolly BH, Dalton L, Smith JB, Lamberth NG, McCay B, Murphy W. Concurrent validity of the Bayley Scales of Infant Development II (BSID-II) Motor Scale and the Peabody Developmental Motor Scale II (PDMS-2) in 12-month-old infants. Pediatr Phys Ther. 2006;18:190\u20136.","journal-title":"Pediatr Phys Ther"},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"103871","DOI":"10.1016\/j.ridd.2021.103871","volume":"111","author":"LW Zanella","year":"2021","unstructured":"Zanella LW, Valentini NC, Copetti F, Nobre GC. Peabody Developmental Motor Scales-Second Edition (PDMS-2): teliability, content and construct validity evidence for Brazilian children. Res Dev Disabil. 2021;111:103871.","journal-title":"Res Dev Disabil"},{"key":"653_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12020-020-02547-3","volume":"71","author":"Y Luo","year":"2021","unstructured":"Luo Y, Zheng Z, Yang Y, Bai X, Yang H, Zhu H, et al. Effects of growth hormone on cognitive, motor, and behavioral development in Prader\u2013Willi syndrome children: a meta-analysis of randomized controlled trials. Endocrine. 2021;71:321\u201330.","journal-title":"Endocrine"},{"key":"653_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ghir.2017.03.001","volume":"34","author":"E Scheermeyer","year":"2017","unstructured":"Scheermeyer E, Harris M, Hughes I, Crock PA, Ambler G, Verge CF, et al. Low dose growth hormone treatment in infants and toddlers with Prader\u2013Willi syndrome is comparable to higher dosage regimens. Growth Horm IGF Res. 2017;34:1\u20137.","journal-title":"Growth Horm IGF Res"},{"key":"653_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13633-020-00090-6","volume":"2020","author":"M Angulo","year":"2020","unstructured":"Angulo M, Abuzzahab MJ, Pietropoli A, Ostrow V, Kelepouris N, Tauber M. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program\u00ae and NordiNet\u00ae International Outcome Study. Int J Pediatr Endocrinol. 2020;2020:20.","journal-title":"Int J Pediatr Endocrinol"},{"key":"653_CR33","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3390\/jcm10143176","volume":"10","author":"A Lecka-Ambroziak","year":"2021","unstructured":"Lecka-Ambroziak A, Wysocka-Mincewicz M, Dolezal-Oltarzewska K, Zygmunt-Gorska A, Wedrychowicz A, Zak T, et al. Effects of recombinant human growth hormone treatment, depending on the therapy start in different nutritional phases in paediatric patients with Prader\u2013Willi syndrome: a Polish multicentre study. J Clin Med. 2021;10:3176.","journal-title":"J Clin Med"},{"key":"653_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4274\/jcrpe.galenos.2019.2018.0277","volume":"11","author":"M Gaddas","year":"2019","unstructured":"Gaddas M, Perin L, Le Bouc Y. Evaluation of IGF1\/IGFBP3 molar ratio as an effective tool for assessing the safety of growth hormone therapy in small-for-gestational-age, growth hormone-deficient and Prader\u2013Willi children. J Clin Res Pediatr Endocrinol. 2019;11:253\u201361.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"653_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/000992289703600602","volume":"36","author":"JM Gerard","year":"1997","unstructured":"Gerard JM, Garibaldi L, Myers SE, Aceto T Jr, Kotagal S, Gibbons VP, et al. Sleep apnea in patients receiving growth hormone. Clin Pediatr (Phila). 1997;36:321\u20136.","journal-title":"Clin Pediatr (Phila)"},{"key":"653_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13023-020-01527-0","volume":"15","author":"L Magill","year":"2020","unstructured":"Magill L, Laemmer C, Woelfle J, Fimmers R, Gohlke B. Early start of growth hormone is associated with positive effects on auxology and metabolism in Prader\u2013Willi-syndrome. Orphanet J Rare Dis. 2020;15:283.","journal-title":"Orphanet J Rare Dis"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-022-00653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-022-00653-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-022-00653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T08:41:40Z","timestamp":1701592900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-022-00653-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,24]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s12519-022-00653-y","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,24]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, informed consent form, case report form, investigator\u2019s manual, and other related documents were approved by the Medical Ethics Committee of the Children's Hospital of Fudan University (reference number: 2018\/135). The study was conducted in compliance with the Declaration of Helsinki and Good Clinical Practices and was approved by the institutional review board of each study site. Informed consent to participate in the study has been obtained from the participant\u2019s legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. Authors Jun-Fen Fu and Xiao-Ping Luo are members of the International Editorial Board for <i>World Journal of Pediatrics<\/i>. The paper was handled by the other Editor and has undergone rigorous peer review process. Authors Jun-Fen Fu and Xiao-Ping Luo were not involved in the journal's review of, or decisions related to, this manuscript. All other authors have no competing interests. GeneScience Pharmaceuticals Co., Ltd has no conflict of interest with this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}